nodes	percent_of_prediction	percent_of_DWPC	metapath
Formoterol—CYP2D6—Temsirolimus—kidney cancer	0.114	0.227	CbGbCtD
Formoterol—CYP2C9—Capecitabine—kidney cancer	0.0683	0.136	CbGbCtD
Formoterol—CYP2D6—Pazopanib—kidney cancer	0.0599	0.119	CbGbCtD
Formoterol—CYP2C19—Sorafenib—kidney cancer	0.0457	0.0911	CbGbCtD
Formoterol—CYP2C9—Paclitaxel—kidney cancer	0.0428	0.0853	CbGbCtD
Formoterol—CYP2D6—Erlotinib—kidney cancer	0.0428	0.0852	CbGbCtD
Formoterol—CYP2C9—Sorafenib—kidney cancer	0.038	0.0758	CbGbCtD
Formoterol—CYP2D6—Sorafenib—kidney cancer	0.0348	0.0693	CbGbCtD
Formoterol—CYP2D6—Vinblastine—kidney cancer	0.0343	0.0684	CbGbCtD
Formoterol—CYP2D6—Doxorubicin—kidney cancer	0.0211	0.042	CbGbCtD
Formoterol—Isoprenaline—MAPK1—kidney cancer	0.00375	0.508	CrCbGaD
Formoterol—Dobutamine—CA2—kidney cancer	0.00283	0.383	CrCbGaD
Formoterol—Isoprenaline—CYP1A1—kidney cancer	0.000806	0.109	CrCbGaD
Formoterol—Connective tissue disorder—Capecitabine—kidney cancer	0.000278	0.0006	CcSEcCtD
Formoterol—Vomiting—Everolimus—kidney cancer	0.000278	0.000599	CcSEcCtD
Formoterol—Urethral disorder—Capecitabine—kidney cancer	0.000278	0.000599	CcSEcCtD
Formoterol—Agitation—Paclitaxel—kidney cancer	0.000276	0.000596	CcSEcCtD
Formoterol—Rash—Everolimus—kidney cancer	0.000275	0.000594	CcSEcCtD
Formoterol—Dermatitis—Everolimus—kidney cancer	0.000275	0.000594	CcSEcCtD
Formoterol—Headache—Vinblastine—kidney cancer	0.000275	0.000593	CcSEcCtD
Formoterol—Angioedema—Paclitaxel—kidney cancer	0.000274	0.000592	CcSEcCtD
Formoterol—Headache—Everolimus—kidney cancer	0.000274	0.000591	CcSEcCtD
Formoterol—Hypotension—Gemcitabine—kidney cancer	0.000274	0.00059	CcSEcCtD
Formoterol—Abdominal pain—Dactinomycin—kidney cancer	0.000273	0.000589	CcSEcCtD
Formoterol—Body temperature increased—Dactinomycin—kidney cancer	0.000273	0.000589	CcSEcCtD
Formoterol—Visual impairment—Capecitabine—kidney cancer	0.000273	0.000589	CcSEcCtD
Formoterol—Asthenia—Sorafenib—kidney cancer	0.000272	0.000587	CcSEcCtD
Formoterol—Malaise—Paclitaxel—kidney cancer	0.000271	0.000584	CcSEcCtD
Formoterol—Hypoglycaemia—Doxorubicin—kidney cancer	0.00027	0.000583	CcSEcCtD
Formoterol—Hypersensitivity—Sunitinib—kidney cancer	0.000269	0.00058	CcSEcCtD
Formoterol—Pruritus—Sorafenib—kidney cancer	0.000268	0.000579	CcSEcCtD
Formoterol—Vomiting—Erlotinib—kidney cancer	0.000268	0.000578	CcSEcCtD
Formoterol—Musculoskeletal discomfort—Gemcitabine—kidney cancer	0.000267	0.000576	CcSEcCtD
Formoterol—Gastrointestinal disorder—Vincristine—kidney cancer	0.000266	0.000575	CcSEcCtD
Formoterol—Fatigue—Vincristine—kidney cancer	0.000266	0.000574	CcSEcCtD
Formoterol—Rash—Erlotinib—kidney cancer	0.000266	0.000573	CcSEcCtD
Formoterol—Dermatitis—Erlotinib—kidney cancer	0.000265	0.000573	CcSEcCtD
Formoterol—Palpitations—Paclitaxel—kidney cancer	0.000265	0.000573	CcSEcCtD
Formoterol—Insomnia—Gemcitabine—kidney cancer	0.000265	0.000571	CcSEcCtD
Formoterol—Headache—Erlotinib—kidney cancer	0.000264	0.00057	CcSEcCtD
Formoterol—Constipation—Vincristine—kidney cancer	0.000264	0.000569	CcSEcCtD
Formoterol—Pain—Vincristine—kidney cancer	0.000264	0.000569	CcSEcCtD
Formoterol—Cardiac disorder—Capecitabine—kidney cancer	0.000263	0.000567	CcSEcCtD
Formoterol—Cough—Paclitaxel—kidney cancer	0.000262	0.000566	CcSEcCtD
Formoterol—Asthenia—Sunitinib—kidney cancer	0.000262	0.000565	CcSEcCtD
Formoterol—Dyspnoea—Gemcitabine—kidney cancer	0.000261	0.000563	CcSEcCtD
Formoterol—Nausea—Vinblastine—kidney cancer	0.00026	0.000562	CcSEcCtD
Formoterol—Somnolence—Gemcitabine—kidney cancer	0.00026	0.000562	CcSEcCtD
Formoterol—Nausea—Everolimus—kidney cancer	0.000259	0.00056	CcSEcCtD
Formoterol—Diarrhoea—Sorafenib—kidney cancer	0.000259	0.00056	CcSEcCtD
Formoterol—Hypertension—Paclitaxel—kidney cancer	0.000259	0.00056	CcSEcCtD
Formoterol—Pruritus—Sunitinib—kidney cancer	0.000258	0.000557	CcSEcCtD
Formoterol—Immune system disorder—Capecitabine—kidney cancer	0.000256	0.000552	CcSEcCtD
Formoterol—Chest pain—Paclitaxel—kidney cancer	0.000256	0.000552	CcSEcCtD
Formoterol—Myalgia—Paclitaxel—kidney cancer	0.000256	0.000552	CcSEcCtD
Formoterol—Arthralgia—Paclitaxel—kidney cancer	0.000256	0.000552	CcSEcCtD
Formoterol—Mediastinal disorder—Capecitabine—kidney cancer	0.000255	0.000551	CcSEcCtD
Formoterol—Anxiety—Paclitaxel—kidney cancer	0.000255	0.00055	CcSEcCtD
Formoterol—Hypersensitivity—Dactinomycin—kidney cancer	0.000254	0.000549	CcSEcCtD
Formoterol—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—kidney cancer	0.000254	0.000548	CcSEcCtD
Formoterol—Arrhythmia—Capecitabine—kidney cancer	0.000253	0.000546	CcSEcCtD
Formoterol—Gastrointestinal disorder—Gemcitabine—kidney cancer	0.000253	0.000545	CcSEcCtD
Formoterol—Discomfort—Paclitaxel—kidney cancer	0.000253	0.000545	CcSEcCtD
Formoterol—Fatigue—Gemcitabine—kidney cancer	0.000252	0.000545	CcSEcCtD
Formoterol—Gastrointestinal pain—Vincristine—kidney cancer	0.000252	0.000545	CcSEcCtD
Formoterol—Dizziness—Sorafenib—kidney cancer	0.000251	0.000541	CcSEcCtD
Formoterol—Pain—Gemcitabine—kidney cancer	0.00025	0.00054	CcSEcCtD
Formoterol—Constipation—Gemcitabine—kidney cancer	0.00025	0.00054	CcSEcCtD
Formoterol—Nausea—Erlotinib—kidney cancer	0.00025	0.00054	CcSEcCtD
Formoterol—Dry mouth—Paclitaxel—kidney cancer	0.00025	0.00054	CcSEcCtD
Formoterol—Diarrhoea—Sunitinib—kidney cancer	0.00025	0.000539	CcSEcCtD
Formoterol—Mental disorder—Capecitabine—kidney cancer	0.000248	0.000535	CcSEcCtD
Formoterol—Asthenia—Dactinomycin—kidney cancer	0.000248	0.000535	CcSEcCtD
Formoterol—Malnutrition—Capecitabine—kidney cancer	0.000246	0.000532	CcSEcCtD
Formoterol—Dehydration—Doxorubicin—kidney cancer	0.000245	0.000529	CcSEcCtD
Formoterol—Anaphylactic shock—Paclitaxel—kidney cancer	0.000245	0.000529	CcSEcCtD
Formoterol—Oedema—Paclitaxel—kidney cancer	0.000245	0.000529	CcSEcCtD
Formoterol—Abdominal pain—Vincristine—kidney cancer	0.000244	0.000526	CcSEcCtD
Formoterol—Body temperature increased—Vincristine—kidney cancer	0.000244	0.000526	CcSEcCtD
Formoterol—Infection—Paclitaxel—kidney cancer	0.000244	0.000525	CcSEcCtD
Formoterol—Dry skin—Doxorubicin—kidney cancer	0.000242	0.000522	CcSEcCtD
Formoterol—Dysgeusia—Capecitabine—kidney cancer	0.000241	0.000521	CcSEcCtD
Formoterol—Dizziness—Sunitinib—kidney cancer	0.000241	0.000521	CcSEcCtD
Formoterol—Feeling abnormal—Gemcitabine—kidney cancer	0.000241	0.000521	CcSEcCtD
Formoterol—Vomiting—Sorafenib—kidney cancer	0.000241	0.00052	CcSEcCtD
Formoterol—Nervous system disorder—Paclitaxel—kidney cancer	0.00024	0.000519	CcSEcCtD
Formoterol—Hypokalaemia—Doxorubicin—kidney cancer	0.00024	0.000518	CcSEcCtD
Formoterol—Tachycardia—Paclitaxel—kidney cancer	0.000239	0.000516	CcSEcCtD
Formoterol—Rash—Sorafenib—kidney cancer	0.000239	0.000516	CcSEcCtD
Formoterol—Dermatitis—Sorafenib—kidney cancer	0.000239	0.000515	CcSEcCtD
Formoterol—Back pain—Capecitabine—kidney cancer	0.000238	0.000514	CcSEcCtD
Formoterol—Skin disorder—Paclitaxel—kidney cancer	0.000238	0.000514	CcSEcCtD
Formoterol—Headache—Sorafenib—kidney cancer	0.000238	0.000513	CcSEcCtD
Formoterol—Muscle spasms—Capecitabine—kidney cancer	0.000237	0.000511	CcSEcCtD
Formoterol—Diarrhoea—Dactinomycin—kidney cancer	0.000236	0.00051	CcSEcCtD
Formoterol—Nasopharyngitis—Doxorubicin—kidney cancer	0.000236	0.000509	CcSEcCtD
Formoterol—Gastritis—Doxorubicin—kidney cancer	0.000233	0.000504	CcSEcCtD
Formoterol—Vomiting—Sunitinib—kidney cancer	0.000232	0.000501	CcSEcCtD
Formoterol—Body temperature increased—Gemcitabine—kidney cancer	0.000231	0.000499	CcSEcCtD
Formoterol—Tremor—Capecitabine—kidney cancer	0.000231	0.000498	CcSEcCtD
Formoterol—Rash—Sunitinib—kidney cancer	0.00023	0.000496	CcSEcCtD
Formoterol—Dermatitis—Sunitinib—kidney cancer	0.00023	0.000496	CcSEcCtD
Formoterol—Hypotension—Paclitaxel—kidney cancer	0.000229	0.000494	CcSEcCtD
Formoterol—Ill-defined disorder—Capecitabine—kidney cancer	0.000229	0.000493	CcSEcCtD
Formoterol—Headache—Sunitinib—kidney cancer	0.000229	0.000493	CcSEcCtD
Formoterol—Asthma—Doxorubicin—kidney cancer	0.000228	0.000492	CcSEcCtD
Formoterol—Influenza—Doxorubicin—kidney cancer	0.000228	0.000492	CcSEcCtD
Formoterol—Hypersensitivity—Vincristine—kidney cancer	0.000227	0.000491	CcSEcCtD
Formoterol—Nausea—Sorafenib—kidney cancer	0.000225	0.000486	CcSEcCtD
Formoterol—Musculoskeletal discomfort—Paclitaxel—kidney cancer	0.000223	0.000482	CcSEcCtD
Formoterol—Malaise—Capecitabine—kidney cancer	0.000222	0.00048	CcSEcCtD
Formoterol—Angina pectoris—Doxorubicin—kidney cancer	0.000222	0.000479	CcSEcCtD
Formoterol—Insomnia—Paclitaxel—kidney cancer	0.000222	0.000478	CcSEcCtD
Formoterol—Asthenia—Vincristine—kidney cancer	0.000221	0.000478	CcSEcCtD
Formoterol—Vomiting—Dactinomycin—kidney cancer	0.00022	0.000474	CcSEcCtD
Formoterol—Bronchitis—Doxorubicin—kidney cancer	0.000219	0.000473	CcSEcCtD
Formoterol—Dyspnoea—Paclitaxel—kidney cancer	0.000219	0.000472	CcSEcCtD
Formoterol—Somnolence—Paclitaxel—kidney cancer	0.000218	0.00047	CcSEcCtD
Formoterol—Palpitations—Capecitabine—kidney cancer	0.000218	0.00047	CcSEcCtD
Formoterol—Rash—Dactinomycin—kidney cancer	0.000218	0.00047	CcSEcCtD
Formoterol—Nausea—Sunitinib—kidney cancer	0.000217	0.000468	CcSEcCtD
Formoterol—Dyspepsia—Paclitaxel—kidney cancer	0.000216	0.000466	CcSEcCtD
Formoterol—Cough—Capecitabine—kidney cancer	0.000215	0.000464	CcSEcCtD
Formoterol—Hypertension—Capecitabine—kidney cancer	0.000213	0.000459	CcSEcCtD
Formoterol—Upper respiratory tract infection—Doxorubicin—kidney cancer	0.000212	0.000457	CcSEcCtD
Formoterol—Gastrointestinal disorder—Paclitaxel—kidney cancer	0.000212	0.000457	CcSEcCtD
Formoterol—Fatigue—Paclitaxel—kidney cancer	0.000211	0.000456	CcSEcCtD
Formoterol—Diarrhoea—Vincristine—kidney cancer	0.000211	0.000456	CcSEcCtD
Formoterol—Asthenia—Gemcitabine—kidney cancer	0.00021	0.000453	CcSEcCtD
Formoterol—Myalgia—Capecitabine—kidney cancer	0.00021	0.000453	CcSEcCtD
Formoterol—Chest pain—Capecitabine—kidney cancer	0.00021	0.000453	CcSEcCtD
Formoterol—Arthralgia—Capecitabine—kidney cancer	0.00021	0.000453	CcSEcCtD
Formoterol—Pain—Paclitaxel—kidney cancer	0.00021	0.000452	CcSEcCtD
Formoterol—Constipation—Paclitaxel—kidney cancer	0.00021	0.000452	CcSEcCtD
Formoterol—Anxiety—Capecitabine—kidney cancer	0.000209	0.000451	CcSEcCtD
Formoterol—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—kidney cancer	0.000208	0.00045	CcSEcCtD
Formoterol—Discomfort—Capecitabine—kidney cancer	0.000207	0.000447	CcSEcCtD
Formoterol—Pruritus—Gemcitabine—kidney cancer	0.000207	0.000447	CcSEcCtD
Formoterol—Hyperglycaemia—Doxorubicin—kidney cancer	0.000206	0.000444	CcSEcCtD
Formoterol—Dry mouth—Capecitabine—kidney cancer	0.000205	0.000443	CcSEcCtD
Formoterol—Nausea—Dactinomycin—kidney cancer	0.000205	0.000443	CcSEcCtD
Formoterol—Dizziness—Vincristine—kidney cancer	0.000204	0.00044	CcSEcCtD
Formoterol—Feeling abnormal—Paclitaxel—kidney cancer	0.000202	0.000436	CcSEcCtD
Formoterol—Oedema—Capecitabine—kidney cancer	0.000201	0.000434	CcSEcCtD
Formoterol—Gastrointestinal pain—Paclitaxel—kidney cancer	0.0002	0.000433	CcSEcCtD
Formoterol—Diarrhoea—Gemcitabine—kidney cancer	0.0002	0.000432	CcSEcCtD
Formoterol—Infection—Capecitabine—kidney cancer	0.0002	0.000431	CcSEcCtD
Formoterol—Conjunctivitis—Doxorubicin—kidney cancer	0.000198	0.000426	CcSEcCtD
Formoterol—Urinary tract infection—Doxorubicin—kidney cancer	0.000198	0.000426	CcSEcCtD
Formoterol—Nervous system disorder—Capecitabine—kidney cancer	0.000197	0.000426	CcSEcCtD
Formoterol—Tachycardia—Capecitabine—kidney cancer	0.000196	0.000424	CcSEcCtD
Formoterol—Vomiting—Vincristine—kidney cancer	0.000196	0.000423	CcSEcCtD
Formoterol—Skin disorder—Capecitabine—kidney cancer	0.000195	0.000422	CcSEcCtD
Formoterol—Urticaria—Paclitaxel—kidney cancer	0.000195	0.00042	CcSEcCtD
Formoterol—Rash—Vincristine—kidney cancer	0.000195	0.00042	CcSEcCtD
Formoterol—Dermatitis—Vincristine—kidney cancer	0.000194	0.00042	CcSEcCtD
Formoterol—Haematuria—Doxorubicin—kidney cancer	0.000194	0.000418	CcSEcCtD
Formoterol—Abdominal pain—Paclitaxel—kidney cancer	0.000194	0.000418	CcSEcCtD
Formoterol—Body temperature increased—Paclitaxel—kidney cancer	0.000194	0.000418	CcSEcCtD
Formoterol—Headache—Vincristine—kidney cancer	0.000193	0.000417	CcSEcCtD
Formoterol—Sinusitis—Doxorubicin—kidney cancer	0.000191	0.000412	CcSEcCtD
Formoterol—Hypotension—Capecitabine—kidney cancer	0.000188	0.000406	CcSEcCtD
Formoterol—Vomiting—Gemcitabine—kidney cancer	0.000186	0.000402	CcSEcCtD
Formoterol—Rash—Gemcitabine—kidney cancer	0.000185	0.000398	CcSEcCtD
Formoterol—Dermatitis—Gemcitabine—kidney cancer	0.000184	0.000398	CcSEcCtD
Formoterol—Headache—Gemcitabine—kidney cancer	0.000183	0.000396	CcSEcCtD
Formoterol—Nausea—Vincristine—kidney cancer	0.000183	0.000396	CcSEcCtD
Formoterol—Musculoskeletal discomfort—Capecitabine—kidney cancer	0.000183	0.000395	CcSEcCtD
Formoterol—Rhinitis—Doxorubicin—kidney cancer	0.000183	0.000395	CcSEcCtD
Formoterol—Insomnia—Capecitabine—kidney cancer	0.000182	0.000393	CcSEcCtD
Formoterol—Pharyngitis—Doxorubicin—kidney cancer	0.000181	0.000391	CcSEcCtD
Formoterol—Hypersensitivity—Paclitaxel—kidney cancer	0.000181	0.00039	CcSEcCtD
Formoterol—Urinary tract disorder—Doxorubicin—kidney cancer	0.00018	0.000389	CcSEcCtD
Formoterol—Oedema peripheral—Doxorubicin—kidney cancer	0.00018	0.000388	CcSEcCtD
Formoterol—Connective tissue disorder—Doxorubicin—kidney cancer	0.000179	0.000387	CcSEcCtD
Formoterol—Dyspnoea—Capecitabine—kidney cancer	0.000179	0.000387	CcSEcCtD
Formoterol—Urethral disorder—Doxorubicin—kidney cancer	0.000179	0.000386	CcSEcCtD
Formoterol—Dyspepsia—Capecitabine—kidney cancer	0.000177	0.000382	CcSEcCtD
Formoterol—Visual impairment—Doxorubicin—kidney cancer	0.000176	0.00038	CcSEcCtD
Formoterol—Asthenia—Paclitaxel—kidney cancer	0.000176	0.00038	CcSEcCtD
Formoterol—Nausea—Gemcitabine—kidney cancer	0.000174	0.000375	CcSEcCtD
Formoterol—Gastrointestinal disorder—Capecitabine—kidney cancer	0.000174	0.000375	CcSEcCtD
Formoterol—Fatigue—Capecitabine—kidney cancer	0.000173	0.000374	CcSEcCtD
Formoterol—Pruritus—Paclitaxel—kidney cancer	0.000173	0.000374	CcSEcCtD
Formoterol—Constipation—Capecitabine—kidney cancer	0.000172	0.000371	CcSEcCtD
Formoterol—Pain—Capecitabine—kidney cancer	0.000172	0.000371	CcSEcCtD
Formoterol—Cardiac disorder—Doxorubicin—kidney cancer	0.000169	0.000366	CcSEcCtD
Formoterol—Diarrhoea—Paclitaxel—kidney cancer	0.000168	0.000362	CcSEcCtD
Formoterol—Feeling abnormal—Capecitabine—kidney cancer	0.000166	0.000358	CcSEcCtD
Formoterol—Immune system disorder—Doxorubicin—kidney cancer	0.000165	0.000356	CcSEcCtD
Formoterol—Gastrointestinal pain—Capecitabine—kidney cancer	0.000164	0.000355	CcSEcCtD
Formoterol—Mediastinal disorder—Doxorubicin—kidney cancer	0.000164	0.000355	CcSEcCtD
Formoterol—Arrhythmia—Doxorubicin—kidney cancer	0.000163	0.000352	CcSEcCtD
Formoterol—Dizziness—Paclitaxel—kidney cancer	0.000162	0.00035	CcSEcCtD
Formoterol—Mental disorder—Doxorubicin—kidney cancer	0.00016	0.000345	CcSEcCtD
Formoterol—Urticaria—Capecitabine—kidney cancer	0.00016	0.000345	CcSEcCtD
Formoterol—Abdominal pain—Capecitabine—kidney cancer	0.000159	0.000343	CcSEcCtD
Formoterol—Body temperature increased—Capecitabine—kidney cancer	0.000159	0.000343	CcSEcCtD
Formoterol—Malnutrition—Doxorubicin—kidney cancer	0.000159	0.000343	CcSEcCtD
Formoterol—Tension—Doxorubicin—kidney cancer	0.000156	0.000336	CcSEcCtD
Formoterol—Vomiting—Paclitaxel—kidney cancer	0.000156	0.000336	CcSEcCtD
Formoterol—Dysgeusia—Doxorubicin—kidney cancer	0.000156	0.000336	CcSEcCtD
Formoterol—Rash—Paclitaxel—kidney cancer	0.000155	0.000334	CcSEcCtD
Formoterol—Dermatitis—Paclitaxel—kidney cancer	0.000154	0.000333	CcSEcCtD
Formoterol—Nervousness—Doxorubicin—kidney cancer	0.000154	0.000333	CcSEcCtD
Formoterol—Back pain—Doxorubicin—kidney cancer	0.000154	0.000332	CcSEcCtD
Formoterol—Headache—Paclitaxel—kidney cancer	0.000154	0.000331	CcSEcCtD
Formoterol—Muscle spasms—Doxorubicin—kidney cancer	0.000153	0.00033	CcSEcCtD
Formoterol—Hypersensitivity—Capecitabine—kidney cancer	0.000148	0.00032	CcSEcCtD
Formoterol—Ill-defined disorder—Doxorubicin—kidney cancer	0.000147	0.000318	CcSEcCtD
Formoterol—Agitation—Doxorubicin—kidney cancer	0.000146	0.000315	CcSEcCtD
Formoterol—Nausea—Paclitaxel—kidney cancer	0.000146	0.000314	CcSEcCtD
Formoterol—Asthenia—Capecitabine—kidney cancer	0.000144	0.000311	CcSEcCtD
Formoterol—Malaise—Doxorubicin—kidney cancer	0.000143	0.000309	CcSEcCtD
Formoterol—Pruritus—Capecitabine—kidney cancer	0.000142	0.000307	CcSEcCtD
Formoterol—Palpitations—Doxorubicin—kidney cancer	0.00014	0.000303	CcSEcCtD
Formoterol—Cough—Doxorubicin—kidney cancer	0.000139	0.000299	CcSEcCtD
Formoterol—Diarrhoea—Capecitabine—kidney cancer	0.000138	0.000297	CcSEcCtD
Formoterol—Hypertension—Doxorubicin—kidney cancer	0.000137	0.000296	CcSEcCtD
Formoterol—Arthralgia—Doxorubicin—kidney cancer	0.000135	0.000292	CcSEcCtD
Formoterol—Chest pain—Doxorubicin—kidney cancer	0.000135	0.000292	CcSEcCtD
Formoterol—Myalgia—Doxorubicin—kidney cancer	0.000135	0.000292	CcSEcCtD
Formoterol—Anxiety—Doxorubicin—kidney cancer	0.000135	0.000291	CcSEcCtD
Formoterol—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—kidney cancer	0.000134	0.00029	CcSEcCtD
Formoterol—Discomfort—Doxorubicin—kidney cancer	0.000134	0.000288	CcSEcCtD
Formoterol—Dizziness—Capecitabine—kidney cancer	0.000133	0.000287	CcSEcCtD
Formoterol—Dry mouth—Doxorubicin—kidney cancer	0.000132	0.000285	CcSEcCtD
Formoterol—Oedema—Doxorubicin—kidney cancer	0.00013	0.00028	CcSEcCtD
Formoterol—Anaphylactic shock—Doxorubicin—kidney cancer	0.00013	0.00028	CcSEcCtD
Formoterol—Infection—Doxorubicin—kidney cancer	0.000129	0.000278	CcSEcCtD
Formoterol—Vomiting—Capecitabine—kidney cancer	0.000128	0.000276	CcSEcCtD
Formoterol—Nervous system disorder—Doxorubicin—kidney cancer	0.000127	0.000274	CcSEcCtD
Formoterol—Rash—Capecitabine—kidney cancer	0.000127	0.000274	CcSEcCtD
Formoterol—Dermatitis—Capecitabine—kidney cancer	0.000127	0.000273	CcSEcCtD
Formoterol—Tachycardia—Doxorubicin—kidney cancer	0.000127	0.000273	CcSEcCtD
Formoterol—Headache—Capecitabine—kidney cancer	0.000126	0.000272	CcSEcCtD
Formoterol—Skin disorder—Doxorubicin—kidney cancer	0.000126	0.000272	CcSEcCtD
Formoterol—Hypotension—Doxorubicin—kidney cancer	0.000121	0.000261	CcSEcCtD
Formoterol—Nausea—Capecitabine—kidney cancer	0.000119	0.000258	CcSEcCtD
Formoterol—Musculoskeletal discomfort—Doxorubicin—kidney cancer	0.000118	0.000255	CcSEcCtD
Formoterol—Insomnia—Doxorubicin—kidney cancer	0.000117	0.000253	CcSEcCtD
Formoterol—Dyspnoea—Doxorubicin—kidney cancer	0.000116	0.000249	CcSEcCtD
Formoterol—Somnolence—Doxorubicin—kidney cancer	0.000115	0.000249	CcSEcCtD
Formoterol—Dyspepsia—Doxorubicin—kidney cancer	0.000114	0.000246	CcSEcCtD
Formoterol—Gastrointestinal disorder—Doxorubicin—kidney cancer	0.000112	0.000242	CcSEcCtD
Formoterol—Fatigue—Doxorubicin—kidney cancer	0.000112	0.000241	CcSEcCtD
Formoterol—Constipation—Doxorubicin—kidney cancer	0.000111	0.000239	CcSEcCtD
Formoterol—Pain—Doxorubicin—kidney cancer	0.000111	0.000239	CcSEcCtD
Formoterol—Feeling abnormal—Doxorubicin—kidney cancer	0.000107	0.000231	CcSEcCtD
Formoterol—Gastrointestinal pain—Doxorubicin—kidney cancer	0.000106	0.000229	CcSEcCtD
Formoterol—Urticaria—Doxorubicin—kidney cancer	0.000103	0.000222	CcSEcCtD
Formoterol—Abdominal pain—Doxorubicin—kidney cancer	0.000102	0.000221	CcSEcCtD
Formoterol—Body temperature increased—Doxorubicin—kidney cancer	0.000102	0.000221	CcSEcCtD
Formoterol—Hypersensitivity—Doxorubicin—kidney cancer	9.55e-05	0.000206	CcSEcCtD
Formoterol—Asthenia—Doxorubicin—kidney cancer	9.3e-05	0.000201	CcSEcCtD
Formoterol—Pruritus—Doxorubicin—kidney cancer	9.17e-05	0.000198	CcSEcCtD
Formoterol—Diarrhoea—Doxorubicin—kidney cancer	8.87e-05	0.000191	CcSEcCtD
Formoterol—Dizziness—Doxorubicin—kidney cancer	8.57e-05	0.000185	CcSEcCtD
Formoterol—Vomiting—Doxorubicin—kidney cancer	8.24e-05	0.000178	CcSEcCtD
Formoterol—Rash—Doxorubicin—kidney cancer	8.18e-05	0.000176	CcSEcCtD
Formoterol—Dermatitis—Doxorubicin—kidney cancer	8.17e-05	0.000176	CcSEcCtD
Formoterol—Headache—Doxorubicin—kidney cancer	8.12e-05	0.000175	CcSEcCtD
Formoterol—Nausea—Doxorubicin—kidney cancer	7.7e-05	0.000166	CcSEcCtD
Formoterol—CYP2A6—Metabolism—SLC5A3—kidney cancer	2.93e-05	0.00107	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism of lipids and lipoproteins—CRABP1—kidney cancer	2.9e-05	0.00106	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—PDHB—kidney cancer	2.89e-05	0.00105	CbGpPWpGaD
Formoterol—CYP2C19—Biological oxidations—POMC—kidney cancer	2.88e-05	0.00105	CbGpPWpGaD
Formoterol—ADRB2—GPCR downstream signaling—ANXA1—kidney cancer	2.88e-05	0.00105	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—LDHB—kidney cancer	2.87e-05	0.00105	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—SFRP2—kidney cancer	2.75e-05	0.001	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—CCBL1—kidney cancer	2.72e-05	0.00099	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—SFRP2—kidney cancer	2.69e-05	0.00098	CbGpPWpGaD
Formoterol—ADRB1—Signaling by GPCR—ANXA1—kidney cancer	2.67e-05	0.000974	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—PDHB—kidney cancer	2.66e-05	0.000969	CbGpPWpGaD
Formoterol—CYP2D6—Biological oxidations—POMC—kidney cancer	2.65e-05	0.000966	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism of lipids and lipoproteins—CRABP1—kidney cancer	2.64e-05	0.000963	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—PDHB—kidney cancer	2.63e-05	0.00096	CbGpPWpGaD
Formoterol—CYP2C9—Biological oxidations—POMC—kidney cancer	2.63e-05	0.000957	CbGpPWpGaD
Formoterol—ADRB2—Signaling by GPCR—ANXA1—kidney cancer	2.61e-05	0.000953	CbGpPWpGaD
Formoterol—ADRB1—GPCR ligand binding—POMC—kidney cancer	2.55e-05	0.00093	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—CCBL1—kidney cancer	2.5e-05	0.000911	CbGpPWpGaD
Formoterol—ADRB2—GPCR ligand binding—POMC—kidney cancer	2.49e-05	0.000909	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—CA9—kidney cancer	2.49e-05	0.000907	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—CCBL1—kidney cancer	2.48e-05	0.000903	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism of lipids and lipoproteins—ACHE—kidney cancer	2.46e-05	0.000895	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—PPAT—kidney cancer	2.35e-05	0.000858	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—GLIPR1—kidney cancer	2.35e-05	0.000858	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism of lipids and lipoproteins—SCARB1—kidney cancer	2.32e-05	0.000848	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism of lipids and lipoproteins—PTGS1—kidney cancer	2.3e-05	0.000839	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism of lipids and lipoproteins—ACHE—kidney cancer	2.24e-05	0.000816	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—AKAP13—kidney cancer	2.21e-05	0.000807	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—CASP2—kidney cancer	2.21e-05	0.000807	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—FH—kidney cancer	2.19e-05	0.000798	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—APRT—kidney cancer	2.19e-05	0.000798	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—AKAP13—kidney cancer	2.17e-05	0.00079	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—CASP2—kidney cancer	2.17e-05	0.00079	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—PPAT—kidney cancer	2.17e-05	0.00079	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—GLIPR1—kidney cancer	2.17e-05	0.00079	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—PPAT—kidney cancer	2.15e-05	0.000783	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—GLIPR1—kidney cancer	2.15e-05	0.000783	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism of lipids and lipoproteins—BCHE—kidney cancer	2.14e-05	0.00078	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism of lipids and lipoproteins—SCARB1—kidney cancer	2.12e-05	0.000773	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—CRABP1—kidney cancer	2.12e-05	0.000771	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism of lipids and lipoproteins—PTGS1—kidney cancer	2.1e-05	0.000765	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—GPC3—kidney cancer	2.06e-05	0.00075	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—GRB7—kidney cancer	2.03e-05	0.000738	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—APRT—kidney cancer	2.01e-05	0.000734	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—FH—kidney cancer	2.01e-05	0.000734	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—CA2—kidney cancer	2e-05	0.00073	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—FH—kidney cancer	2e-05	0.000728	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—APRT—kidney cancer	2e-05	0.000728	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—GRB7—kidney cancer	1.98e-05	0.000722	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—ITPR2—kidney cancer	1.97e-05	0.000717	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—ALAD—kidney cancer	1.95e-05	0.000711	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism of lipids and lipoproteins—BCHE—kidney cancer	1.95e-05	0.000711	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—ST3GAL2—kidney cancer	1.9e-05	0.000694	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—GPC3—kidney cancer	1.89e-05	0.00069	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—ITPR2—kidney cancer	1.88e-05	0.000687	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—GPC3—kidney cancer	1.88e-05	0.000684	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—ALDH1A1—kidney cancer	1.86e-05	0.000679	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—ITPR2—kidney cancer	1.84e-05	0.000672	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—CA2—kidney cancer	1.84e-05	0.000671	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—CA2—kidney cancer	1.83e-05	0.000666	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—ALAD—kidney cancer	1.79e-05	0.000654	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—GSTT1—kidney cancer	1.79e-05	0.000654	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—ACHE—kidney cancer	1.79e-05	0.000654	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—PGK1—kidney cancer	1.78e-05	0.000651	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—SLC5A3—kidney cancer	1.78e-05	0.000651	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—ALAD—kidney cancer	1.78e-05	0.000649	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—ST3GAL2—kidney cancer	1.75e-05	0.000639	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—LDHB—kidney cancer	1.75e-05	0.000638	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—ST3GAL2—kidney cancer	1.74e-05	0.000633	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—ALDH1A1—kidney cancer	1.71e-05	0.000624	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—CTNNA1—kidney cancer	1.71e-05	0.000622	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—SCARB1—kidney cancer	1.7e-05	0.000619	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—HSPB1—kidney cancer	1.7e-05	0.000619	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—EIF4EBP1—kidney cancer	1.7e-05	0.000619	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—ALDH1A1—kidney cancer	1.7e-05	0.000619	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—PTGS1—kidney cancer	1.68e-05	0.000613	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—CTNNA1—kidney cancer	1.67e-05	0.000609	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—EIF4EBP1—kidney cancer	1.66e-05	0.000605	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—HSPB1—kidney cancer	1.66e-05	0.000605	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—PSMD7—kidney cancer	1.65e-05	0.000601	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—PGK1—kidney cancer	1.64e-05	0.000598	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—SLC5A3—kidney cancer	1.64e-05	0.000598	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—SLC5A3—kidney cancer	1.63e-05	0.000593	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—PGK1—kidney cancer	1.63e-05	0.000593	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—LDHB—kidney cancer	1.61e-05	0.000587	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—LDHB—kidney cancer	1.6e-05	0.000582	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—PSMD7—kidney cancer	1.58e-05	0.000575	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—TSC1—kidney cancer	1.58e-05	0.000575	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—ANXA1—kidney cancer	1.58e-05	0.000575	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—BCHE—kidney cancer	1.56e-05	0.00057	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—SLC5A5—kidney cancer	1.54e-05	0.000563	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—PSMD7—kidney cancer	1.54e-05	0.000563	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—TSC1—kidney cancer	1.54e-05	0.000563	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—ANXA1—kidney cancer	1.54e-05	0.000563	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—FLT1—kidney cancer	1.53e-05	0.000557	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—CA9—kidney cancer	1.52e-05	0.000553	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—FLT1—kidney cancer	1.49e-05	0.000545	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—SLC2A1—kidney cancer	1.49e-05	0.000544	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism of lipids and lipoproteins—CYP1A1—kidney cancer	1.48e-05	0.000541	CbGpPWpGaD
Formoterol—ADRB1—GPCR downstream signaling—POMC—kidney cancer	1.44e-05	0.000525	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—JUNB—kidney cancer	1.42e-05	0.000516	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—PAK1—kidney cancer	1.42e-05	0.000516	CbGpPWpGaD
Formoterol—ADRB2—GPCR downstream signaling—POMC—kidney cancer	1.41e-05	0.000514	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—CA9—kidney cancer	1.4e-05	0.000509	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—JUNB—kidney cancer	1.39e-05	0.000505	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—PAK1—kidney cancer	1.39e-05	0.000505	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—CA9—kidney cancer	1.38e-05	0.000504	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—kidney cancer	1.35e-05	0.000493	CbGpPWpGaD
Formoterol—ADRB1—Signaling by GPCR—POMC—kidney cancer	1.31e-05	0.000477	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—CRABP1—kidney cancer	1.29e-05	0.00047	CbGpPWpGaD
Formoterol—ADRB2—Signaling by GPCR—POMC—kidney cancer	1.28e-05	0.000467	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—GSTP1—kidney cancer	1.24e-05	0.000453	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—ITPR2—kidney cancer	1.2e-05	0.000437	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—CRABP1—kidney cancer	1.19e-05	0.000433	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—ABCB1—kidney cancer	1.18e-05	0.000429	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—CRABP1—kidney cancer	1.18e-05	0.000429	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—IGF2—kidney cancer	1.16e-05	0.000422	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—CDKN2B—kidney cancer	1.15e-05	0.00042	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—GSTM1—kidney cancer	1.14e-05	0.000417	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—IGF2—kidney cancer	1.13e-05	0.000413	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—CDKN2B—kidney cancer	1.13e-05	0.000411	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—IGF1R—kidney cancer	1.12e-05	0.000408	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism of lipids and lipoproteins—POMC—kidney cancer	1.11e-05	0.000403	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—ITPR2—kidney cancer	1.1e-05	0.000402	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—IGF1R—kidney cancer	1.1e-05	0.000399	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—ACHE—kidney cancer	1.09e-05	0.000399	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—GSTT1—kidney cancer	1.09e-05	0.000399	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—ITPR2—kidney cancer	1.09e-05	0.000399	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—CYP1A1—kidney cancer	1.08e-05	0.000395	CbGpPWpGaD
Formoterol—ADRB1—Signaling by GPCR—RAF1—kidney cancer	1.08e-05	0.000393	CbGpPWpGaD
Formoterol—ADRB1—GPCR downstream signaling—IL2—kidney cancer	1.07e-05	0.000388	CbGpPWpGaD
Formoterol—ADRB2—Signaling by GPCR—RAF1—kidney cancer	1.06e-05	0.000385	CbGpPWpGaD
Formoterol—ADRB2—GPCR downstream signaling—IL2—kidney cancer	1.04e-05	0.00038	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—SCARB1—kidney cancer	1.04e-05	0.000377	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—PTGS1—kidney cancer	1.02e-05	0.000374	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism of lipids and lipoproteins—POMC—kidney cancer	1.01e-05	0.000368	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—GSTT1—kidney cancer	1.01e-05	0.000367	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—ACHE—kidney cancer	1.01e-05	0.000367	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—PSMD7—kidney cancer	1.01e-05	0.000366	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—GSTT1—kidney cancer	9.97e-06	0.000364	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—ACHE—kidney cancer	9.97e-06	0.000364	CbGpPWpGaD
Formoterol—ADRB1—Signaling by GPCR—IL2—kidney cancer	9.67e-06	0.000353	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—BCHE—kidney cancer	9.53e-06	0.000347	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—SCARB1—kidney cancer	9.52e-06	0.000347	CbGpPWpGaD
Formoterol—ADRB2—Signaling by GPCR—IL2—kidney cancer	9.46e-06	0.000345	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—SCARB1—kidney cancer	9.44e-06	0.000344	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—PTGS1—kidney cancer	9.43e-06	0.000344	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—SLC5A5—kidney cancer	9.41e-06	0.000343	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—PTGS1—kidney cancer	9.35e-06	0.000341	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—PSMD7—kidney cancer	9.24e-06	0.000337	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—HIF1A—kidney cancer	9.22e-06	0.000336	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—TSC2—kidney cancer	9.2e-06	0.000335	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—PSMD7—kidney cancer	9.16e-06	0.000334	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—SLC2A1—kidney cancer	9.09e-06	0.000331	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—HIF1A—kidney cancer	9.02e-06	0.000329	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—TSC2—kidney cancer	9e-06	0.000328	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	8.82e-06	0.000322	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—KDR—kidney cancer	8.82e-06	0.000321	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—BCHE—kidney cancer	8.76e-06	0.00032	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—BCHE—kidney cancer	8.69e-06	0.000317	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—SLC5A5—kidney cancer	8.66e-06	0.000316	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—KDR—kidney cancer	8.62e-06	0.000314	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—SLC5A5—kidney cancer	8.58e-06	0.000313	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—SLC2A1—kidney cancer	8.36e-06	0.000305	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—SLC2A1—kidney cancer	8.29e-06	0.000302	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—KIT—kidney cancer	8.12e-06	0.000296	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—APC—kidney cancer	8.12e-06	0.000296	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—POMC—kidney cancer	8.08e-06	0.000294	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	8.04e-06	0.000293	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—KIT—kidney cancer	7.94e-06	0.00029	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—APC—kidney cancer	7.94e-06	0.00029	CbGpPWpGaD
Formoterol—ADRB1—Signaling by GPCR—MAPK3—kidney cancer	7.78e-06	0.000284	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—POMC—kidney cancer	7.73e-06	0.000282	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	7.69e-06	0.00028	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—BRAF—kidney cancer	7.63e-06	0.000278	CbGpPWpGaD
Formoterol—ADRB2—Signaling by GPCR—MAPK3—kidney cancer	7.61e-06	0.000277	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—GSTP1—kidney cancer	7.58e-06	0.000276	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—POMC—kidney cancer	7.56e-06	0.000276	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—BRAF—kidney cancer	7.47e-06	0.000272	CbGpPWpGaD
Formoterol—ADRB1—Signaling by GPCR—MAPK1—kidney cancer	7.4e-06	0.00027	CbGpPWpGaD
Formoterol—ADRB2—Signaling by GPCR—MAPK1—kidney cancer	7.24e-06	0.000264	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—ABCB1—kidney cancer	7.18e-06	0.000262	CbGpPWpGaD
Formoterol—ADRB1—GPCR downstream signaling—PIK3CA—kidney cancer	7.07e-06	0.000258	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	7.01e-06	0.000256	CbGpPWpGaD
Formoterol—ADRB1—Signaling by GPCR—KRAS—kidney cancer	6.99e-06	0.000255	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—GSTP1—kidney cancer	6.97e-06	0.000254	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—GSTM1—kidney cancer	6.97e-06	0.000254	CbGpPWpGaD
Formoterol—ADRB2—GPCR downstream signaling—PIK3CA—kidney cancer	6.92e-06	0.000252	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—GSTP1—kidney cancer	6.91e-06	0.000252	CbGpPWpGaD
Formoterol—ADRB2—Signaling by GPCR—KRAS—kidney cancer	6.84e-06	0.000249	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—CYP1A1—kidney cancer	6.6e-06	0.000241	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—ABCB1—kidney cancer	6.6e-06	0.000241	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—ABCB1—kidney cancer	6.54e-06	0.000239	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—PTGS2—kidney cancer	6.44e-06	0.000235	CbGpPWpGaD
Formoterol—ADRB1—Signaling by GPCR—PIK3CA—kidney cancer	6.42e-06	0.000234	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—GSTM1—kidney cancer	6.41e-06	0.000234	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—RAF1—kidney cancer	6.37e-06	0.000232	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—GSTM1—kidney cancer	6.35e-06	0.000232	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—RELA—kidney cancer	6.35e-06	0.000231	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—ERBB2—kidney cancer	6.31e-06	0.00023	CbGpPWpGaD
Formoterol—ADRB2—Signaling by GPCR—PIK3CA—kidney cancer	6.28e-06	0.000229	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—RAF1—kidney cancer	6.24e-06	0.000227	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—MTOR—kidney cancer	6.22e-06	0.000227	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—RELA—kidney cancer	6.21e-06	0.000226	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—ERBB2—kidney cancer	6.17e-06	0.000225	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—MTOR—kidney cancer	6.09e-06	0.000222	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—CYP1A1—kidney cancer	6.07e-06	0.000221	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—CYP1A1—kidney cancer	6.02e-06	0.00022	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—CDKN1B—kidney cancer	5.84e-06	0.000213	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—IL2—kidney cancer	5.72e-06	0.000208	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—CDKN1B—kidney cancer	5.71e-06	0.000208	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—PTEN—kidney cancer	5.62e-06	0.000205	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—IL2—kidney cancer	5.59e-06	0.000204	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—CCND1—kidney cancer	5.57e-06	0.000203	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—JUN—kidney cancer	5.56e-06	0.000203	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—CTNNB1—kidney cancer	5.52e-06	0.000201	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—CCND1—kidney cancer	5.45e-06	0.000199	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—JUN—kidney cancer	5.44e-06	0.000198	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	5.43e-06	0.000198	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—CTNNB1—kidney cancer	5.4e-06	0.000197	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—PTEN—kidney cancer	5.38e-06	0.000196	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—PTEN—kidney cancer	5.26e-06	0.000192	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	4.95e-06	0.00018	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—POMC—kidney cancer	4.92e-06	0.00018	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—VEGFA—kidney cancer	4.86e-06	0.000177	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—VEGFA—kidney cancer	4.75e-06	0.000173	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—MAPK3—kidney cancer	4.59e-06	0.000168	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—POMC—kidney cancer	4.53e-06	0.000165	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—MAPK3—kidney cancer	4.49e-06	0.000164	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—POMC—kidney cancer	4.49e-06	0.000164	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—MYC—kidney cancer	4.47e-06	0.000163	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—MAPK1—kidney cancer	4.37e-06	0.000159	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—MYC—kidney cancer	4.37e-06	0.000159	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—MAPK1—kidney cancer	4.28e-06	0.000156	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—KRAS—kidney cancer	4.13e-06	0.000151	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—KRAS—kidney cancer	4.04e-06	0.000147	CbGpPWpGaD
Formoterol—CYP2A6—Metabolism—PIK3CA—kidney cancer	3.96e-06	0.000144	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—PTGS2—kidney cancer	3.93e-06	0.000143	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—PIK3CA—kidney cancer	3.79e-06	0.000138	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—PIK3CA—kidney cancer	3.71e-06	0.000135	CbGpPWpGaD
Formoterol—ADRB1—Signaling Pathways—TP53—kidney cancer	3.67e-06	0.000134	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—PTGS2—kidney cancer	3.61e-06	0.000132	CbGpPWpGaD
Formoterol—ADRB2—Signaling Pathways—TP53—kidney cancer	3.59e-06	0.000131	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—PTGS2—kidney cancer	3.58e-06	0.000131	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—PTEN—kidney cancer	3.43e-06	0.000125	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—PTEN—kidney cancer	3.15e-06	0.000115	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—PTEN—kidney cancer	3.12e-06	0.000114	CbGpPWpGaD
Formoterol—CYP2C19—Metabolism—PIK3CA—kidney cancer	2.42e-06	8.81e-05	CbGpPWpGaD
Formoterol—CYP2D6—Metabolism—PIK3CA—kidney cancer	2.22e-06	8.1e-05	CbGpPWpGaD
Formoterol—CYP2C9—Metabolism—PIK3CA—kidney cancer	2.2e-06	8.03e-05	CbGpPWpGaD
